Acquired Inhibitors to Multiple Coagulation Factors (V, IX, and XII) Identified in a Unique Patient with Hepatocellular Carcinoma

Internal Medicine
Osamu ImatakiMakiko Uemura

Abstract

An acquired formation of inhibitors to coagulation factors is a rare type of coagulopathy. The development of inhibitors for multiple coagulation factors has never been reported. A 75-year-old Japanese female underwent interventional therapy for hepatocellular carcinoma. Five days after the last intervention, her prothrombin time decreased to 10%, and her activated partial thromboplastin time (APTT) lengthened to 265.1 sec. The activities for coagulation factors showed significantly reduced activities (<10%) of factors V, IX, and XII. A cross-mixing test demonstrated an inhibitor pattern, and inhibitory antibodies against factors V, IX, and XII were detected. We discuss our patient's etiology and pathogenesis.

References

Oct 29, 1991·Biochemistry·E W DavieW Kisiel
Mar 31, 1999·Baillière's Clinical Haematology·P Knöbl, K Lechner
Oct 31, 2003·American Journal of Hematology·Emmanuelle de RaucourtCatherine Ternisien
Mar 15, 2008·Nature Reviews. Immunology·Hajime Kono, Kenneth L Rock
Oct 10, 2009·British Journal of Haematology·Peter W Collins, Charles L Percy
Apr 20, 2010·Haemophilia : the Official Journal of the World Federation of Hemophilia·J AstermarkUNKNOWN European Haemophilia Therapy Standardisation Board
Dec 19, 2015·European Journal of Haematology·Craig M Kessler, Paul Knöbl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.